ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025
Access of medication review for people living with dementia: An analysis of inequality using Swedish register data.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Access of medication review for people living with dementia: An analysis of inequality using Swedish register data.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionThis study examines medication reviews (MRs) among people living with dementia (PWD) in Sweden, focusing on frequency and factors influencing access.
methodsUsing nationwide register data, all diagnosed PWD from 2010 to 2016 were assessed for MR receipt in 2015 and/or 2016. The analysis guided by the Andersen healthcare utilization framework, considered predisposing, enabling, and need-based factors through multiple logistic regression.
resultsThe MR rate was 16% in 2015, 21% in 2016, and 30% across both years. Increased MR likelihood was linked to higher comorbidity (adjusted odds ratio [aOR] = 1.45, p = 0.00), polypharmacy (aOR = 1.55, p = 0.00), and residential care (aOR = 3.92, p = 0.00), while being married or cohabiting reduced (aOR = 0.80, p = 0.00) MR receipt. DISCUSSION: Despite national guidelines recommending annual MRs since 2012, rates remain low, especially outside residential care. The findings highlight the need for more equitable MR access for all PWD, particularly those not in residential care. HIGHLIGHTS: Only 16%-21% of people with dementia received a medication review in 2015-2016 in Sweden. Higher comorbidity, polypharmacy, and residential care increased likelihood of receiving a medication review. Being married or cohabiting lowered the chance of receiving a medication review. Education level and gender did not affect access to medication reviews.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.